Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
O'Neil long-acting naltrexone implant study in substance dependence
ACTRN12609000682246Phase 3Not yet recruiting
- Sponsor
- Go Medical Industries
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of O'Neil long-acting naltrexone implant in substance use disorder (SUD) and opioid use disorder (OUD), sponsored by Go Medical Industries. Primary endpoints: Adverse events during and after implant effect and Adverse events in hospital and health service records. Planned start Aug 2009; status: not yet recruiting.
02
Drugs
O'Neil long-acting naltrexone implant
03
Conditions
substance use disorder (SUD)opioid use disorder (OUD)
Beyond the preview
Go deeper on ACTRN12609000682246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000682246.